Product Data Sheet

Visilizumab

Cat. No.:	HY-P99332	
CAS No.:	219716-33-3	
Target:	Apoptosis	
Pathway:	Apoptosis	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
Description	Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research ^[1] .		
In Vitro	Visilizumab induces dose- and time-dependent apoptosis of lamina propria T cells. Visilizumab-induces apoptosis of lamina propria T cells is dependent on caspase 3 and 8, but not caspase 9 activation and does not involve the Fas/FasL pathway ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis Analysis ^[1]		
	Cell Line: Concentration:	Lamina propria T cells 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL	
	Incubation Time:	2 hours, 4 hours, 20 hours, 24 hours, 48 hours	
	Result:	Induced dose- and time-dependent apoptosis of lamina propria T cells.	

REFERENCES

[1]. Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

